Molecular Evolution of Early-Onset Prostate Cancer Identifies Molecular Risk Markers and Clinical Trajectories

Clarissa Gerhauser, Francesco Favero, Thomas Risch, Ronald Simon, Lars Feuerbach, Yassen Assenov, Doreen Heckmann, Nikos Sidiropoulos, Sebastian M. Waszak, Daniel Hübschmann, Alfonso Urbanucci, Etsehiwot G. Girma, Vladimir Kuryshev, Leszek J. Klimczak, Natalie Saini, Adrian M. Stütz, Dieter Weichenhan, Lisa Marie Böttcher, Reka Toth, Josephine D. HendriksenChristina Koop, Pavlo Lutsik, Sören Matzk, Hans Jörg Warnatz, Vyacheslav Amstislavskiy, Clarissa Feuerstein, Benjamin Raeder, Olga Bogatyrova, Eva Maria Schmitz, Claudia Hube-Magg, Martina Kluth, Hartwig Huland, Markus Graefen, Chris Lawerenz, Gervaise H. Henry, Takafumi N. Yamaguchi, Alicia Malewska, Jan Meiners, Daniela Schilling, Eva Reisinger, Roland Eils, Matthias Schlesner, Douglas W. Strand, Robert G. Bristow, Paul C. Boutros, Christof von Kalle, Dmitry Gordenin, Holger Sültmann, Benedikt Brors, Guido Sauter, Christoph Plass, Marie Laure Yaspo, Jan O. Korbel, Thorsten Schlomm, Joachim Weischenfeldt

Research output: Contribution to journalArticle

26 Scopus citations

Abstract

Identifying the earliest somatic changes in prostate cancer can give important insights into tumor evolution and aids in stratifying high- from low-risk disease. We integrated whole genome, transcriptome and methylome analysis of early-onset prostate cancers (diagnosis ≤55 years). Characterization across 292 prostate cancer genomes revealed age-related genomic alterations and a clock-like enzymatic-driven mutational process contributing to the earliest mutations in prostate cancer patients. Our integrative analysis identified four molecular subgroups, including a particularly aggressive subgroup with recurrent duplications associated with increased expression of ESRP1, which we validate in 12,000 tissue microarray tumors. Finally, we combined the patterns of molecular co-occurrence and risk-based subgroup information to deconvolve the molecular and clinical trajectories of prostate cancer from single patient samples. Gerhauser et al. molecularly characterize prostate cancers diagnosed before 56 years old, which reveals an APOBEC-driven mutational process and identifies an aggressive subgroup with increased expression of ESRP1. They develop a framework to predict the order of somatic alterations and clinical outcome.

Original languageEnglish (US)
Pages (from-to)996-1011.e8
JournalCancer Cell
Volume34
Issue number6
DOIs
StatePublished - Dec 10 2018

Keywords

  • APOBEC
  • cancer genomics
  • early-onset cancer
  • epigenetic risk-score
  • mutational processes
  • prostate cancer
  • structural variants
  • tumor evolution
  • tumor evolution prediction

ASJC Scopus subject areas

  • Oncology
  • Cell Biology
  • Cancer Research

Fingerprint Dive into the research topics of 'Molecular Evolution of Early-Onset Prostate Cancer Identifies Molecular Risk Markers and Clinical Trajectories'. Together they form a unique fingerprint.

  • Cite this

    Gerhauser, C., Favero, F., Risch, T., Simon, R., Feuerbach, L., Assenov, Y., Heckmann, D., Sidiropoulos, N., Waszak, S. M., Hübschmann, D., Urbanucci, A., Girma, E. G., Kuryshev, V., Klimczak, L. J., Saini, N., Stütz, A. M., Weichenhan, D., Böttcher, L. M., Toth, R., ... Weischenfeldt, J. (2018). Molecular Evolution of Early-Onset Prostate Cancer Identifies Molecular Risk Markers and Clinical Trajectories. Cancer Cell, 34(6), 996-1011.e8. https://doi.org/10.1016/j.ccell.2018.10.016